Clover Corp Ltd (ASX: CLV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clover Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $82.66 million
P/E Ratio 43.53
Dividend Yield 1.49%
Shares Outstanding 167.00 million
Earnings per share 0.012
Dividend per share 0.02
Year To Date Return -38.79%
Earnings Yield 2.30%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clover Corp Ltd (ASX: CLV)
    Latest News

    A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
    52-Week Lows

    3 ASX shares sinking to 52-week lows today

    These ASX shares are having a bit of a nightmare this year.

    Read more »

    two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
    Share Gainers

    Why Bannerman, Clover, Polynovo, and Pro Medicus shares are pushing higher

    Not all shares are falling with the market on Tuesday. Here's why they are rising.

    Read more »

    $50 dollar Australian notes in the back pocket of jeans representing dividends.
    Dividend Investing

    5 ASX All Ords shares trading ex-dividend this week

    These five All Ords shares might have a bumpy week this week.

    Read more »

    A man points at a paper as he holds an alarm clock.
    Dividend Investing

    Here are 3 ASX All Ords shares turning ex-dividend this week

    These dividends will soon be taken off the table.

    Read more »

    Three happy young women wearing headphones dance to music.
    Share Gainers

    Why Clover, Select Harvests, Whitehaven Coal, and Woodside shares are storming higher

    These ASX shares are storming higher on Thursday...

    Read more »

    a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
    Share Gainers

    3 ASX All Ordinaries shares defying today's rout to surge higher

    These ASX All Ords shares are bucking today's sell-off.

    Read more »

    An older man leaping into the air with joy in the Australian outback.
    Dividend Investing

    Here are 5 ASX shares trading ex-dividend this week

    These shares will be cutting off new investors from an upcoming dividend this week.

    Read more »

    ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
    Share Fallers

    Clover (ASX:CLV) share price sinks 7% on FY 2021 results

    It was a tough year for this specialist ingredients company...

    Read more »

    Happy retirees celebrate with wine over lunch
    Dividend Investing

    2 ASX dividend shares that could provide steady income retirement

    Brickworks is one of the ASX dividend shares that could provide steady income.

    Read more »

    A businesman's hands surround a circular graphic with a United States flag and dollar signs, indicating buying and selling US shares
    Share Market News

    ASX investors couldn't get enough of meme stocks last week

    ASX investors can't seem to get enough of the meme stock...

    Read more »

    falling milk asx share price represented by frowning woman tasting sour milk
    Consumer Staples & Discretionary Shares

    Will 2021 go down as the year A2 and other milk share prices turned sour?

    Infant formula used to be a booming sector. Yet, 2021 is shaping up to be a shocking year for the…

    Read more »

    A compass with the word opportunities is shown in black and blue representing a broker upgrade on the EML share price
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    These 3 ASX shares have been named as buys by leading brokers, including healthcare business Volpara Health Technologies Ltd (ASX:VHT).

    Read more »

    Frequently Asked Questions

    Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.

    Clover Corporation generally pays its dividends in April and November.

    No, Clover Corporation does not have a dividend reinvestment plan at the current time. 

    Clover Corporation listed on the ASX on 30 November 1999.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    30 Oct 2023 $0.0075 100.00% Final 20 Nov 2023
    05 Apr 2023 $0.0075 100.00% Interim 27 Apr 2023
    25 Oct 2022 $0.0100 100.00% Final 22 Nov 2022
    06 Apr 2022 $0.0050 100.00% Interim 28 Apr 2022
    25 Oct 2021 $0.0050 100.00% Final 16 Nov 2021
    07 Apr 2021 $0.0050 100.00% Interim 29 Apr 2021
    27 Oct 2020 $0.0250 100.00% Final 18 Nov 2020
    29 Oct 2019 $0.0175 100.00% Final 20 Nov 2019
    08 Apr 2019 $0.0063 100.00% Interim 30 Apr 2019
    29 Oct 2018 $0.0125 100.00% Final 20 Nov 2018
    09 Apr 2018 $0.0050 100.00% Interim 01 May 2018
    27 Oct 2017 $0.0000 100.00% Final 20 Nov 2017
    10 Apr 2017 $0.0025 100.00% Interim 01 May 2017
    27 Oct 2016 $0.0050 100.00% Final 21 Nov 2016
    11 Apr 2016 $0.0025 100.00% Interim 02 May 2016
    29 Nov 2010 $0.0125 100.00% Final 15 Dec 2010

    CLV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clover Corp Ltd

    Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.

    Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market. 

    CLV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jun 2024 $0.50 $-0.01 -1.98% 112 $0.50 $0.50 $0.50
    13 Jun 2024 $0.51 $0.01 2.00% 39,203 $0.50 $0.51 $0.50
    12 Jun 2024 $0.50 $0.00 0.00% 30,000 $0.50 $0.50 $0.50
    11 Jun 2024 $0.50 $0.00 0.00% 25,779 $0.50 $0.50 $0.50
    07 Jun 2024 $0.50 $0.00 0.00% 41,570 $0.50 $0.50 $0.50
    06 Jun 2024 $0.50 $0.01 2.02% 51,387 $0.50 $0.51 $0.50
    05 Jun 2024 $0.50 $0.00 0.00% 10,374 $0.51 $0.51 $0.50
    04 Jun 2024 $0.50 $-0.01 -2.00% 114,393 $0.50 $0.50 $0.50
    03 Jun 2024 $0.50 $0.00 0.00% 1,774 $0.51 $0.51 $0.50
    30 May 2024 $0.50 $-0.01 -1.98% 54,730 $0.51 $0.51 $0.50
    29 May 2024 $0.51 $-0.01 -1.96% 36,536 $0.51 $0.51 $0.50
    28 May 2024 $0.51 $0.00 0.00% 57,324 $0.51 $0.52 $0.51
    27 May 2024 $0.51 $0.00 0.00% 55,959 $0.51 $0.52 $0.51
    24 May 2024 $0.51 $0.00 0.00% 5,000 $0.51 $0.51 $0.51
    23 May 2024 $0.51 $0.00 0.00% 19,276 $0.51 $0.51 $0.51
    22 May 2024 $0.51 $0.00 0.00% 21,788 $0.51 $0.51 $0.51
    21 May 2024 $0.51 $0.00 0.00% 4,072 $0.51 $0.52 $0.51
    20 May 2024 $0.51 $-0.01 -1.92% 13,425 $0.52 $0.52 $0.51
    17 May 2024 $0.52 $0.01 1.96% 1,967 $0.51 $0.52 $0.51
    16 May 2024 $0.51 $0.00 0.00% 38,111 $0.51 $0.52 $0.51

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Apr 2024 Rupert Harrington Buy 200,000 $99,992
    On-market trade.
    28 Mar 2024 Ian Glasson Buy 20,000 $10,030
    On-market trade.
    28 Mar 2024 Peter Davey Buy 10,000 $5,030
    On-market trade.
    22 Mar 2024 Toni Brendish Buy 16,400 $10,046
    On-market trade.
    13 Dec 2023 Peter Davey Buy 1,136 $909
    On-market trade.
    11 Dec 2023 Peter Davey Buy 20,000 $16,600
    On-market trade.
    23 Nov 2023 Peter Davey Issued 249,712 $194,775
    Issue of securities. 7,54,548 Rights
    23 Nov 2023 Peter Davey Issued 27,266 $21,267
    Conversion of securities.
    23 Nov 2023 Peter Davey Exercise 109,062 $85,068
    Conversion of securities. 645,486 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ian David Glasson Non-Executive Director Feb 2017
    Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout Southeast Asia. Prior to that he was CEO for seven years of Sucrogen (formerly the sugar business of listed entity CSR and now owned by Wilmar) which generated revenues of nearly $2bn and had contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso.
    Ms Toni Brendish Non-Executive Director Oct 2020
    Ms Brendish was most recently Chief Executive of Westland Milk Products in the South Island of New Zealand. Westland produces a range of Dairy products including Infant Formula base powder and was New Zealand's Co-operative prior to being acquired by the Chinese Multinational; Yili. Prior to joining Westland Ms. Brendish worked for the Danone Group for 11 years running their Infant Formula and Dairy businesses including Manufacturing sites across Australia and New Zealand, Malaysia, and Indonesia. She has also worked for Kimberly-Clark, Colgate Palmolive and other Blue Chip FMCG organizations.
    Mr Rupert Anthony Harrington Non-Executive DirectorNon-Executive Chairman Jul 2015
    Mr Harrington is a company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health, and technology. Mr Harrington's earlier career was in operational management in the UK and Australia.
    Mr Graeme Ambery Billings Non-Executive Director May 2013
    Mr Billings was a partner at Coopers and Lybrand and then PricewaterhouseCoopers (PwC) for 24 years. Mr Billings was head of PwC's Melbourne Assurance practice for several years as well as Global Leader of PwC's Industrial Products and Manufacturing industry group. Mr Billings brings a range of financial, corporate governance, internal control, commercial and corporate transactional skills to the Company.
    Mr Peter J Davey Chief Executive OfficerManaging Director Dec 2014
    Mr Davey has a record of building businesses across a diverse range of industry sectors. He has held senior management positions within several manufacturing and distribution companies operating in competitive and diverse markets. Mr Davey has strengths in sales and marketing, and development and implementation of strategies for growth. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed, and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a particular focus on marketing-based businesses operating in the Asia and Oceania regions.
    Dr Simon Green Non-Executive Director Oct 2020
    Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life saving medicines. He was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Dr Green is currently the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics Company. He is also a Venture Partner at BioScience Managers, a healthcare investment firm, and Non-Executive Director at Pharmaxis (chair of the Remuneration and nomination Committee's).
    Mr Andrew Allibon Chief Financial OfficerCompany Secretary May 2021
    -
    Andrew Allibon Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Washington H Soul Pattinson & Company Limited 32,340,217 19.37%
    Citicorp Nominees Pty Limited 23,343,528 13.98%
    UBS Nominees Pty Ltd 14,907,428 8.93%
    Hsbc Custody Nominees (Australia) Limited 12,967,326 7.76%
    J P Morgan Nominees Australia Pty Limited 8,853,419 5.30%
    Evelin Investments Pty Limited 7,550,000 4.52%
    Anacacia Pty Ltd 6,393,701 3.83%
    Incani & Papadopoulos Super Pty Ltd 2,010,000 1.20%
    National Nominees Limited 1,995,837 1.20%
    Mr Peter Howells 1,500,000 0.90%
    Mr Garrie Ellice 1,000,000 0.60%
    Mr Pei Yin Foo 900,000 0.54%
    Baobab Nominees Pty Ltd 861,011 0.52%
    Ms Nina Tschernykow 858,881 0.51%
    Ganesh Super Fund 850,783 0.50%
    Neweconomy Com Au Nominees Pty Limited 798,807 0.48%
    Connaught Consultants (Finance) Pty Ltd 767,000 0.46%
    Bellite Pty Ltd 719,600 0.43%
    Columbus Investment Services Ltd 715,000 0.43%
    Bnp Paribas Noms(Nz) Ltd 700,000 0.42%

    Profile

    since

    Note